One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...

An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...

Patients in London have received a pioneering new gene editing therapy that lowers "bad" cholesterol after a single infusion, ...

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point ...

Drugmaker Eli Lilly is testing a new experimental drug that could be a game changer in treating high cholesterol, it said.

Early CRISPR-based cholesterol therapy shows striking LDL reduction, but experts warn that safety, durability and off-target ...

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

Eli Lilly (LLY) announced that its gene editing candidate VERVE-102, added from its $1.3B acquisition of Verve Therapeutics last year, caused up to a 62% average decline in low-density lipoprotein ...

Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.

PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial ...

Entrepreneur Cathy Tie, often called “Biotech Barbie” has launched a new startup, Origin Genomics, following the closure of her previous firm, Manhattan Genomics, earlier this year.Tie remains focused ...

Researchers developed PRINCE, a small-molecule-controlled CRISPR system enabling precise, long-term regulation of gene editing.